FY2026 Earnings Forecast for Cryoport Issued By Roth Capital

Cryoport, Inc. (NASDAQ:CYRX) – Investment analysts at Roth Capital issued their FY2026 earnings per share estimates for shares of Cryoport in a note issued to investors on Wednesday, March 5th. Roth Capital analyst R. Baldry forecasts that the company will earn ($1.23) per share for the year. The consensus estimate for Cryoport’s current full-year earnings is ($0.99) per share.

Other research analysts have also recently issued reports about the stock. Guggenheim assumed coverage on shares of Cryoport in a report on Thursday, December 19th. They set a “buy” rating and a $11.00 target price on the stock. Roth Mkm cut their price objective on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Cryoport in a report on Wednesday. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.29.

Cryoport Stock Performance

Shares of NASDAQ:CYRX opened at $6.61 on Thursday. The firm’s 50 day simple moving average is $7.34 and its 200-day simple moving average is $7.62. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport has a one year low of $4.58 and a one year high of $20.10. The firm has a market cap of $326.74 million, a PE ratio of -1.96 and a beta of 1.59.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The company had revenue of $59.53 million during the quarter, compared to analysts’ expectations of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same period in the prior year, the business earned ($0.29) EPS.

Institutional Trading of Cryoport

Large investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of Cryoport by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after buying an additional 2,120 shares during the period. Lazard Asset Management LLC purchased a new position in Cryoport in the 4th quarter worth $51,000. Avanza Fonder AB acquired a new stake in Cryoport during the 4th quarter worth about $64,000. Quarry LP purchased a new stake in Cryoport during the 4th quarter valued at about $69,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Cryoport in the third quarter valued at about $82,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.